Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Art Bechhoefer who wrote (52014)	1/10/2023 1:42:31 PM
From: A.J. Mullen	Respond to of 52153

Please take a look at the links I posted. This is from Health Affairs: The IRA includes three main elements to reform Medicare drug pricing policy. First, the IRA provides the Secretary of Health & Human Services (HHS) with the authority to negotiate prescription drug prices for Medicare and requires them to do so, though this authority is more limited than the authority proposed in previous reform packages. Second, the IRA aims to limit the rate at which companies increase the prices of existing prescription drugs in Medicare by requiring the payment of inflationary rebates, a policy which has worked effectively in the Medicaid context. Third, the IRA restructures the Medicare Part D benefit both to limit patients’ out-of-pocket costs and to rebalance the bearing of risk for stakeholders in that program, a policy change which has previously had more bipartisan support than the other two elements. Ashley